Keep track of Closely (one)lenacapavir will raise the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
etravirine will lower the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of fentanyl with CYP3A4 inducers may lead to a lessen in fentanyl plasma concentrations, insufficient efficacy or, possibly, growth of the withdrawal syndrome in the affected individual who's got made Actual physical dependence to fentanyl.
givinostat will boost the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
fentanyl will raise the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
fentanyl and buprenorphine buccal the two enhance sedation. Stay clear of or Use Alternate Drug. Restrict use to patients for whom substitute treatment options are insufficient
Keep track of Carefully (one)viloxazine will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
buprenorphine transdermal and fentanyl each enhance sedation. Avoid or Use Alternate Drug. Limit use to patients for whom substitute treatment options are insufficient
After halting a CYP3A4 fentanyl blues ingredients inducer, as being the effects in the inducer decline, the fentanyl plasma concentration will maximize which could raise or prolong equally the therapeutic and adverse effects.
Your health care provider could swap you to definitely morphine tablets, liquid or another identical painkiller to allow them to lessen the dose more slowly and gradually.
Givinostat can be a weak CYP3A4 inhibitor. Closely keep track of if coadministered with orally administered CYP3A4 delicate substrates for which a small change in substrate plasma concentration might lead to really serious toxicities.
mobocertinib will minimize the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use is unavoidable, maximize CYP3A4 substrate dosage in accordance with its prescribing information.
Observe Carefully (1)dexamethasone will decrease the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of fentanyl with CYP3A4 inducers may lead into a reduce in fentanyl plasma concentrations, not enough efficacy or, potentially, growth of a withdrawal syndrome in a patient that has produced Actual physical dependence to fentanyl.
fentanyl will improve the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Closely. Reduce nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for precise dosage modification.
elranatamab will enhance the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Elranatamab causes cytokine launch syndrome (CRS) that could suppress exercise of CYP enzymes, leading to improved exposure of CYP substrates.